Aphios

What Aphios does

Aphios Corporation is a privately held green biotechnology company founded in 1993 and headquartered in North Reading, Massachusetts. The company develops proprietary enabling technology platforms—Critical Fluid Nanotechnology (CFN), Polymer Nanoparticles (PNP/PNS), CFI pathogen reduction, SuperFluids carbon dioxide-based crystallization, and microbial cell disruption—for drug discovery, manufacturing, drug delivery, and pathogen safety applications. It holds 87 issued U.S. and international patents with 40 pending applications, and supports a therapeutic pipeline spanning oncology (Camposomes, Taxosomes, Dermos, Zindol for CINV), infectious disease (Bryolat HIV latency therapy, nanoHYP, Asterias, Marinus, anti-influenza and HIV candidates, vaccine adjuvants), CNS disorders (APH-1104 for Alzheimer's, CBD nanotherapies for opioid use disorder, chemotherapy-induced peripheral neuropathy, anxiety, multiple sclerosis, epilepsy, and nanoTHC), and diabetes (APH-0907). It also sells clinical-grade dietary supplements (Zindol DS, Sperol DS, Cool Vitamin D, Xantol DS) via direct-to-consumer e-commerce at $26.66–$79.99 per unit.

The company operates through wholly-owned Special Purpose Vehicle LLCs (Aphios Pharma LLC for cannabinoid drugs, Zindol LLC for CINV, Amylon LLC for Alzheimer's, Aphios International LLC for CFI pathogen reduction, Bryolat for HIV) to ring-fence financing and development of individual programs. Revenue mechanics combine (i) one-time and royalty-based licensing of enabling technology platforms to pharmaceutical and biotechnology partners including Boehringer Ingelheim, Abbott, Alkermes, Bristol-Myers Squibb, Eli Lilly, Novartis, Baxter, Bayer, GlaxoSmithKline, and Capsugel; (ii) proprietary therapeutics development financed through SPVs and academic collaborators including Harvard, MIT, Dana-Farber, Boston University, University of Pennsylvania, and University of Michigan; and (iii) direct-to-consumer supplement sales. The company reports cumulative NIH grant funding of approximately $20M, claims a Phase 3-ready asset with $1.6B peak-sales potential, and is positioning itself for potential public-market readiness with a three-member Board of Directors.

Name

Aphios

Legal name

Aphios Corporation

Website

https://aphios.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Aphios Corporation is a green biotechnology company developing proprietary nanotechnology and supercritical fluid platforms for drug discovery, manufacturing, delivery, and pathogen safety, with a therapeutic pipeline spanning oncology, infectious diseases, CNS disorders, diabetes, and clinical-grade dietary supplements.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Discovery and Development

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAGAHAM

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLACAFAL

Connected Therapeutics & Smart Drug Delivery Monitoring

Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

SECONDARYHLAGAHAG

Impurity / Reference Standard Synthesis & Characterization

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAL

GMP Scale-Up, Tech Transfer & Process Validation (PPQ)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

• Green biotechnology platforms
• Nanotechnology drug delivery
• Pathogen reduction technology
• Natural product therapeutics
• Clinical-grade dietary supplements

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Therapeutic Product Development: Developing proprietary therapeutics through SPVs and LLCs for cancer, infectious diseases, and CNS disorders. Revenue potential through product approvals and commercialization.
2. Enabling Technology Licensing: Licensing proprietary green enabling technology platforms to pharmaceutical and biotechnology companies for drug discovery, manufacturing, and drug delivery applications.
3. Dietary Supplements: Direct-to-consumer sales of clinical-grade dietary supplements including Zindol DS, Sperol DS, Cool Vitamin D, and Xantol DS through e-commerce.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Aphios Corporation develops proprietary green enabling technology platforms (CFN, PNS, PNP, CFI, SuperFluids) for drug discovery, pharmaceutical manufacturing, nanotechnology drug delivery, and pathogen safety, and applies these platforms to develop therapeutic products in oncology, infectious disease, CNS disorders, and diabetes. It also sells clinical-grade dietary supplements directly to consumers through e-commerce. The company monetizes through technology licensing to pharma/biotech firms, therapeutic product development via Special Purpose Vehicles, and direct supplement sales.

Product overview

Aphios is a Phase 3-ready platform biotech company with 85+ patents developing differentiated therapeutics across oncology, infectious diseases (including HIV), CNS disorders (Alzheimer's, MS, addiction, pain, anxiety), and diabetes. The portfolio includes therapeutic products (Zindol® for CINV, Camposomes™, Taxosomes™, Dermos™, CBD nanotherapies for OUD/CIPNP/anxiety/MS/epilepsy, APH-1104 for Alzheimer's, HIV therapeutics, vaccine adjuvants) alongside consumer supplements (Zindol® DS ginger, Sperol™ DS saw palmetto, Cool Vitamin D™, Xantol™ DS St. John's Wort). Core enabling technology platforms include Critical Fluid Nanotechnology (CFN), Polymer Nanoparticles (PNP/PNS), CFI® pathogen reduction, and SuperFluids™ crystallization—all supporting drug discovery, manufacturing, and nanotech drug delivery. The company operates through Special Purpose Vehicles (Aphios Pharma LLC for cannabinoid drugs, Zindol® LLC, Amylon™ LLC, Bryolat™ for HIV).

Differentiator

Problem solved

Functional benefit

Brands

• Zindol®: Ginger extract therapy for chemotherapy-induced nausea and vomiting (CINV) and pregnancy-related nausea and vomiting.
• Sperol™
• Cool Vitamin D™
• Xantol™
• Taxosomes™
• Camposomes™
• Dermos™
• nanoHYP™
• nanoTHC™
• Bryolat™

Products and services

• Zindol® Therapeutic (Ginger Extract for CINV) Ginger extract therapy standardized by bioactive constituents gingerols and shogaol for chemotherapy-induced nausea and vomiting (CINV) and pregnancy-related nausea. Targeted by Zindol LLC subsidiary at a $3.4B market.
• Camposomes™ Camptothecin-based nanotechnology drug delivery platform for oncology therapeutics.
• Taxosomes™ Taxane-based nanotechnology drug delivery platform for oncology therapeutics.
• Dermos™ Dermal drug delivery nanotechnology for dermatological therapeutic applications.
• APH-1104 Novel alpha-secretase modulator therapeutic candidate for mild to moderate Alzheimer's disease and other CNS disorders. Developed via Amylon LLC targeting a $19B Alzheimer's market by 2030.
• Xantol™ (Therapeutic) St. John's Wort product standardized by hyperforin content for serotonin reuptake inhibition, intended as a therapeutic for depression and CNS disorders.
• Bryolat™ (APH-0812) HIV Nanotherapy Nanoparticle HIV-1 latency therapy aimed at a functional cure for HIV/AIDS, targeting a $58B HIV market by 2032.
• nanoHYP™ Nanoparticle-based therapeutic product platform for infectious disease applications.
• Asterias™ Infectious disease therapeutic candidate in pipeline using nanotechnology drug delivery.
• Marinus™ Infectious disease therapeutic candidate in pipeline using nanotechnology drug delivery.
• Vaccine Adjuvant Technology Platform Proprietary technology platform for vaccine adjuvant development including anthrax vaccine adjuvant, targeting infectious disease applications.
• Double-Encapsulated Room-Temperature Stable mRNA Vaccine Proprietary double-encapsulated mRNA vaccine technology that maintains stability at room temperature, eliminating cold-chain storage requirements and reducing need for boosters, for COVID-19 and other diseases.
• Zindol® DS Clinical-Grade Ginger Supplement Clinical-grade enhanced ginger supplement standardized by bioactive constituents gingerols and shogaol for nausea relief, chemotherapy-induced nausea and vomiting, and general wellness. Sold at $79.99 per standard bottle. GMP-compliant and FDA-registered.
• Sperol™ DS Saw Palmetto Supplement Enhanced Saw Palmetto dietary supplement standardized on the basis of 5-alpha reductase inhibition for prostate health and healthy hair follicles. Sold at $39.95 per bottle. GMP-compliant and FDA-registered.
• Cool Vitamin D™ Supplement Standardized, stable Vitamin D3 formulation with plant lecithins and emulsifiers for improved bioavailability, supporting cellular and immune function and bone health. GMP-compliant and FDA-registered.
• Xantol™ DS St. John's Wort Supplement Enhanced St. John's Wort dietary supplement standardized by hyperforin content for serotonin reuptake inhibition, supporting emotional well-being and positive mood. GMP-compliant and FDA-registered.
• CFI® Pathogen Reduction Technology Proprietary pathogen reduction technology for biologics, plasma, and human blood supply safety, targeting a $2.5B market. Licensed via Aphios International LLC subsidiary.
• CFN (Critical Fluid Nanotechnology) Platform Critical Fluid Nanotechnology drug delivery platform enabling nanoencapsulation of therapeutics for sustained release in chronic conditions. Available for licensing to pharmaceutical and biotechnology companies.
• PNP/PNS Polymer Nanoparticle Platforms Polymer Nanoparticle (PNP and PNS) drug delivery platforms enabling nanoencapsulation of cannabinoids and other therapeutics for sustained release. Available for licensing.
• SuperFluids™ Crystallization Technology Environmentally-friendly carbon dioxide-based crystallization and fractionation technology using pressurized fluids for natural product isolation, bioactive compound extraction, and pharmaceutical manufacturing.
• Research Chemicals & APIs Catalog Catalog of purified natural product research chemicals and APIs including paclitaxel, camptothecin, bryostatins, hypericin, hyperforin, gingerols, THC/THCA, and other bioactive compounds available for research and pharmaceutical development.

Quantifiable outcome

• 5 to 6 times higher permeability than metoprolol for Xantol DS formulation
• +3 more outcomes

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

34 partnerships are on record, tiered core and secondary.

• Beth Israel Deaconess Medical Center (Harvard Medical School)coreStrategic or Co-development PartnerUniversity research partner for biomedical research collaboration, one of the top recipients of NIH biomedical research funding, affiliated with Joslin Diabetes Center and Dana-Farber/Harvard Cancer Center.
• Boston University School of MedicinecoreStrategic or Co-development PartnerUniversity partner operating the largest 24-hour Level I trauma center in New England with diverse patient base for clinical research.
• Dana-Farber Cancer Institute (Harvard Medical School)coreStrategic or Co-development PartnerNCI-designated Comprehensive Cancer Center, principal teaching affiliate of Harvard Medical School, designated Center for AIDS Research.
• Harvard UniversitycoreStrategic or Co-development PartnerIvy League research university partner for scientific and technological research collaboration.
• Institute of Human Virology, University of MarylandcoreStrategic or Co-development PartnerFirst center in the US combining basic science, epidemiology and clinical research for viral disorders including HIV/AIDS.
• Louisiana State University Health Sciences Center ShreveportsecondaryStrategic or Co-development PartnerAcademic medical center partner for medical research in North Louisiana.
• Massachusetts Institute of Technology (MIT)coreStrategic or Co-development PartnerPremier private research university with strong emphasis on scientific and technological education and research.
• Northeastern UniversitysecondaryStrategic or Co-development PartnerResearch university with specialized research and education centers for life sciences collaboration.
• Perelman School of Medicine, University of PennsylvaniacoreStrategic or Co-development PartnerOldest American medical school offering certificate programs in global health, neuroscience, and aging research.
• Scripps Institution of Oceanography, UC San DiegosecondaryStrategic or Co-development PartnerResearch institution for earth and ocean science studies with relevance to natural product discovery.
• University of Cordoba, SpainsecondaryStrategic or Co-development PartnerInternational university partner focusing on humanities, health sciences and physical sciences.
• University of Michigan College of PharmacycoreStrategic or Co-development PartnerFirst pharmacy school in a US state university, member of prestigious Health Sciences consortium.
• University of Rochester Medical CentersecondaryStrategic or Co-development PartnerMajor medical education, research, and patient care facility in Upstate New York.
• Virginia Tech Department of ChemistrysecondaryStrategic or Co-development PartnerChemistry department with strong international reputation for scientific research.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerFederal cancer research institute coordinating National Cancer Program, conducting and supporting cancer research, training physicians and scientists.
• National Institute of Allergy and Infectious Diseases (NIAID)coreStrategic or Co-development PartnerFederal institute conducting research on infectious, immunologic and allergic diseases; funded Aphios NIH grants.
• National Institute on Drug Abuse (NIDA)coreStrategic or Co-development PartnerFederal institute bringing science to bear on drug abuse and addiction research.
• National Institute on Aging (NIA)coreStrategic or Co-development PartnerDivision of NIH leading scientific effort to understand aging and extend healthy, active years of life.
• National Heart, Lung, and Blood Institute (NHLBI)coreStrategic or Co-development PartnerFederal institute supporting research to prevent and treat heart, lung and blood diseases.
• American Red CrosscoreStrategic or Co-development PartnerUSA's premier emergency response organization involved in blood collection and pathogen safety research.
• Food and Drug Administration (FDA)coreStrategic or Co-development PartnerFederal agency responsible for protecting public health through regulation of pharmaceuticals, biologics, and medical devices.
• National Science Foundation (NSF)coreStrategic or Co-development PartnerFederal agency supporting fundamental research and education in non-medical fields of science and engineering.
• National Institute for Biological Standards and Control (NIBSC)coreStrategic or Co-development PartnerUK research center developing and producing biological international standards, testing biological medicines.
• Boehringer Ingelheim Pharma GmbHcoreTechnology or IntegrationOne of the world's 20 leading pharmaceutical companies with focus on respiratory disease, cardiovascular disease, Parkinson's disease, HIV, thromboembolic disease.
• Abbott LaboratoriescoreTechnology or IntegrationGlobal health care company discovering new medicines, technologies and health management products spanning nutritional products, diagnostics, medical devices and pharmaceutical therapies.
• AlkermescoreTechnology or IntegrationFully integrated global biopharmaceutical company focused on CNS disorders including schizophrenia, addiction, and depression.
• Bristol-Myers SquibbcoreTechnology or IntegrationGlobal BioPharma company manufacturing prescription pharmaceuticals in cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
• Eli LillycoreTechnology or IntegrationWorld's largest manufacturer and distributor of medications for psychiatric and mental health conditions including depression, anxiety, narcotic addiction, insomnia, bipolar disorder and schizophrenia.
• NovartiscoreTechnology or IntegrationMultinational pharmaceutical company with Consumer Health and Biomedical Research divisions developing innovative healthcare solutions.
• Baxter HealthcarecoreTechnology or IntegrationDevelops, manufactures and markets products for hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and chronic medical conditions using medical devices, pharmaceuticals, and biotechnology.
• Bayer Group (Miles Laboratories)coreTechnology or IntegrationGlobal enterprise with core competencies in health care, nutrition, and high-tech materials serving patients and improving quality of life.
• GlaxoSmithKline (SmithKline Beecham)coreTechnology or IntegrationBritish multinational pharmaceutical, biologics, vaccines, and consumer healthcare company with portfolio for asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions.
• Capsugel (ex-Pfizer)coreTechnology or IntegrationWorld leader in capsule manufacturing providing Licaps liquid capsules for pharmaceutical and dietary supplement encapsulation.
• Sigma-AldrichsecondaryTechnology or IntegrationLife science and high technology company providing chemical and biochemical products, kits for scientific research, biotechnology, pharmaceutical development and disease diagnosis.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nanobiotix: Clinical-stage nanomedicine company developing proprietary nano-drug delivery and radio-enhancer platforms for oncology. Highly comparable to Aphios's Camposomes/Taxosomes/Dermos oncology nanotech programs and its CFN/PNS/PNP delivery platforms.
• Jazz Pharmaceuticals: Through its acquisition of GW Pharmaceuticals, Jazz owns the leading pharmaceutical cannabinoid franchises (Sativex, Epidiolex) targeting MS, epilepsy and CNS indications — directly comparable to Aphios Pharma LLC's nano-THC/CBD CNS pipeline.
• Selecta Biosciences: Clinical-stage biotech using nanoparticle immune tolerance and targeted antigen delivery platforms. Comparable in technology architecture and therapeutic positioning to Aphios's polymer nanoparticle (PNS/PNP) and CFN delivery platforms.
• CytoDyn: Clinical-stage biotech pursuing HIV functional cure and oncology indications, with a nanoparticle-enabled therapeutic approach. Overlaps directly with Aphios's Bryolat HIV-1 latency nanoparticle therapy and oncology supportive-care positioning.
• Cassava Sciences: Late-stage CNS biotech focused on Alzheimer's disease therapeutics, comparable to Aphios's APH-1104 alpha-secretase modulator program (Amylon LLC). Both target a $19B+ Alzheimer's market with novel mechanisms.
• Lipocine: Specialty pharma using proprietary lipid-based oral drug delivery platforms to improve bioavailability of small molecules. Comparable to Aphios's SuperFluids crystallization and CFN delivery approaches for difficult-to-formulate actives.
• Acadia Pharmaceuticals: Commercial CNS-focused biotech with franchises in psychosis, Rett syndrome and neurology adjacencies. Comparable to Aphios's CNS pipeline across depression (Xantol), anxiety (APH-1503), MS (APH-1504), epilepsy (APH-1505) and OUD (APH-1501).
• Tilray Brands: Cannabinoid-focused life sciences company with pharmaceutical and consumer businesses. Comparable to Aphios's dual strategy of pharmaceutical-grade cannabinoid drug development (Aphios Pharma LLC) plus consumer supplements (Zindol DS, Sperol DS).

Broad incumbents

• Moderna: mRNA vaccine and therapeutic platform leader. Comparable to Aphios's NIH-funded room-temperature stable mRNA vaccine program; serves as both a benchmark and a potential partner/competitor for that specific asset.
• Pacira BioSciences: Specialty pharma commercializing sustained-release injectable delivery platforms. Relevant comparable for Aphios's nanoparticle sustained-release claim across its CBD nanotherapy and oncology programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/aphios
• YouTubeyoutube.com/channel/UCXArghX04gEpGN2ppuvPlFA
• Facebookfacebook.com/155794624433466
• LinkedInlinkedin.com/company/2678893
• Instagraminstagram.com/aphiosbio
• TikToktiktok.com/@trevorpcastor?lang=en

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aphios